Skip to main content

Main navigation

  • About
    • Members
    • Our Team
    • Annual Report
    • Rutgers-NPC Health Policy & Communications Fellowship
    • NPC Summer Scholars
    • Contact Us
  • Topics
    • Health Spending
      • IRA & Medicare Drug Price Negotiation
      • 340B Drug Pricing Program
      • Understanding Health Spending
      • Low-Value Care
      • Health Spend Management
    • Value Assessment
      • Value Assessment Frameworks
      • Value Assessment Methods
      • Elements of Value
    • Alternative Payment Models
      • Value-Based Contracts
      • Regulatory Barriers & Challenges
      • Paying for Cures
      • Accountable Care Organizations
      • Bundled Payments
      • Health Care Quality Measures
      • Clinical Pathways
    • Patient-Centered Formulary & Benefit Design
      • High-Deductible Health Plans
      • Value-Based Insurance Design
      • Utilization Management & Step Therapy
      • Formulary Development
      • Patient Cost Sharing
      • Individual Treatment Effects & Personalized Access
    • Evidence for Decision Making
      • Real-World Data
      • Real-World Evidence
      • Good Practices for Evidence
    • Biopharma Innovation
      • Impact on Outcomes & Spending
  • Resources
    • Research
    • Fact Sheets
    • Policy & Evidence Briefs
    • Letters & Comments
    • E.V.I.dently Today Blog
    • Newsletters
    • Events
    • CER Daily Newsfeed®
    • Press Room
      • NPC in the News
      • NPC Press Releases
    • Videos and Graphics
    • Stakeholder Resources
      • For Employers
      • For Patient Organizations
      • Going Below The Surface
  • Get Involved
    • Become a Member
    • Submit a Research Proposal
    • Start a Career
National Pharmaceutical Council

Offscreen menu

User account menu

  • Member Resources

Section 50 of the Inflation Reduction Act Drug Price Negotiation Program: Considerations for the Centers for Medicare Medicaid Services, Manufacturers, and the Health Economics and Outcomes Research Community

  • Read more about Section 50 of the Inflation Reduction Act Drug Price Negotiation Program: Considerations for the Centers for Medicare Medicaid Services, Manufacturers, and the Health Economics and Outcomes Research Community

How the Inflation Reduction Act Could Delay Pharmaceutical Launches, Reduce Indications, and Chill Evidence Generation

  • Read more about How the Inflation Reduction Act Could Delay Pharmaceutical Launches, Reduce Indications, and Chill Evidence Generation

Oncology Drug Development: A Drug-Level Analysis of Subsequent Indications

  • Read more about Oncology Drug Development: A Drug-Level Analysis of Subsequent Indications

NPC Submits Comments to CMS on Medicaid Drug Rebate Program

  • Read more about NPC Submits Comments to CMS on Medicaid Drug Rebate Program

NPC Comments on CMS' Drug Price Negotiation Counteroffer Information Collection Request

  • Read more about NPC Comments on CMS' Drug Price Negotiation Counteroffer Information Collection Request

NPC Comments on CMS Information Collection Request for Negotiation Data Elements

  • Read more about NPC Comments on CMS Information Collection Request for Negotiation Data Elements

NPC Comments on CMS Medicare Drug Price Negotiation Program

  • Read more about NPC Comments on CMS Medicare Drug Price Negotiation Program

Affordability Is About More Than Drug Prices

  • Read more about Affordability Is About More Than Drug Prices

How Can We Address Barriers to Accessing Needed Care?

  • Read more about How Can We Address Barriers to Accessing Needed Care?

Breaking Down Regulatory Barriers to Value Pricing for Prescription Drugs

  • Read more about Breaking Down Regulatory Barriers to Value Pricing for Prescription Drugs

Pagination

  • Next page
  • Page 5
  • Next page
Subscribe to Policy & Regulatory Barriers

Let's stay in touch.

Subscribe to our newsletter.
© 2026 NPC. All rights reserved.

Footer Menu

  • Accessibility
  • Privacy Policy
  • Terms of Use
  • Contact Us

Footer Social Links Menu

  • Twitter image/svg+xml
  • Linkedin
  • Youtube